These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 17081923)

  • 1. Clinical response of cutaneous squamous-cell carcinoma to bortezomib given for myeloma.
    Ramadan KM; McKenna KE; Morris TC
    Lancet Oncol; 2006 Nov; 7(11):958-9. PubMed ID: 17081923
    [No Abstract]   [Full Text] [Related]  

  • 2. Bortezomib-induced cutaneous lesions in multiple myeloma patients: a case report.
    Rodríguez-Martín M; Sáez-Rodríguez M; García-Bustínduy M; Martín-Herrera A; Noda-Cabrera A
    Dermatol Online J; 2008 Nov; 14(11):14. PubMed ID: 19094852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple myeloma therapies.
    Strobeck M
    Nat Rev Drug Discov; 2007 Mar; 6(3):181-2. PubMed ID: 17396289
    [No Abstract]   [Full Text] [Related]  

  • 4. Novel agents in myeloma: an exciting saga.
    Mark T; Niesvizky R; Coleman M
    Cancer; 2009 Jan; 115(2):236-42. PubMed ID: 19025986
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of multiple myeloma: 2009 update.
    Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
    Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
    Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib, thalidomide, and dexamethasone for relapsed multiple myeloma: add it up and wait.
    Badros A; Gahres N
    Clin Adv Hematol Oncol; 2005 Dec; 3(12):916-7; discussion 918. PubMed ID: 16555432
    [No Abstract]   [Full Text] [Related]  

  • 8. Improvement of zoledronic-acid-induced jaw osteonecrosis with bortezomib.
    Timurağaoğlu A; Ozkaynak C; Tuzuner S; Bostan F; Undar L
    Acta Haematol; 2007; 118(4):203-4. PubMed ID: 17992010
    [No Abstract]   [Full Text] [Related]  

  • 9. [Multiple myeloma].
    Iida S
    Rinsho Ketsueki; 2012 Feb; 53(2):155-63. PubMed ID: 22450574
    [No Abstract]   [Full Text] [Related]  

  • 10. Bortezomib in the front-line treatment of multiple myeloma.
    Richardson PG; Mitsiades C; Schlossman R; Ghobrial I; Hideshima T; Munshi N; Anderson KC
    Expert Rev Anticancer Ther; 2008 Jul; 8(7):1053-72. PubMed ID: 18588451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of multiple myeloma with bortezomib: experts review the data and debate the issues.
    Dicato M; Boccadoro M; Cavenagh J; Harousseau JL; Ludwig H; San Miguel J; Sonneveld P
    Oncology; 2006; 70(6):474-82. PubMed ID: 17283449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel agents for relapsed and/or refractory multiple myeloma.
    Thomas SK; Richards TA; Weber DM
    Cancer J; 2009; 15(6):485-93. PubMed ID: 20010168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Testicular invading refractory multiple myeloma during bortezomib treatment successfully treated with lenalidomide: a case report.
    Miyao K; Sakemura R; Sakai T; Tsushita N; Kato T; Niimi K; Ono Y; Sawa M
    Ann Hematol; 2014 Mar; 93(3):529-30. PubMed ID: 23820941
    [No Abstract]   [Full Text] [Related]  

  • 14. [Observational retrospective study to evaluate the effectiveness and safety of treatment schemes with bortezomib for multiple myeloma in our hospital].
    Titos-Arcos JC; León-Villar J; de Arriba de la Fuente F; Moreno Belmonte MJ; Iranzo Fernández MD
    Farm Hosp; 2012; 36(4):275-81. PubMed ID: 22115856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.
    Petrucci MT; Giraldo P; Corradini P; Teixeira A; Dimopoulos MA; Blau IW; Drach J; Angermund R; Allietta N; Broer E; Mitchell V; Bladé J
    Br J Haematol; 2013 Mar; 160(5):649-59. PubMed ID: 23293914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myeloma.
    Offidani M; Corvatta L; Polloni C; Gentili S; Mele A; Rizzi R; Catarini M; Caraffa P; Samori A; Blasi N; Ferranti M; Malerba L; Brunori M; Leoni P
    Ann Hematol; 2011 Dec; 90(12):1449-56. PubMed ID: 21437586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing response rates in clinical trials of treatment for relapsed or refractory multiple myeloma: a study of bortezomib and thalidomide.
    Prince HM; Schenkel B; Mileshkin L
    Leukemia; 2007 Apr; 21(4):818-20; author reply 821. PubMed ID: 17301817
    [No Abstract]   [Full Text] [Related]  

  • 18. Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma.
    Vogl DT; Stadtmauer EA; Richardson PG; Sonneveld P; Schuster MW; Irwin D; Facon T; Harousseau JL; Boral A; Neuwirth R; Anderson KC
    Br J Haematol; 2009 Nov; 147(4):531-4. PubMed ID: 19725827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: a Chinese experience.
    Zheng W; Wei G; Ye X; He J; Li L; Wu W; Shi J; Zhang J; Huang W; Xie W; Luo Y; Xue X; Lin M; Huang H; Cai Z
    Leuk Res; 2009 Dec; 33(12):1615-8. PubMed ID: 19773080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib therapy following first relapse.
    Orlowski RZ;
    Oncology (Williston Park); 2005 Jan; 19(1):23-6. PubMed ID: 15743149
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.